Open
Do thiazolidinediones improve all-cause mortality more than other treatments?
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
No claim has formed for this comparison yet. The trials below are registered, but none decides it.
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 3
- With posted results
- 2
- Published papers
- 4
Papers
- The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.Meta-analysis / systematic review · 2022
- Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.Meta-analysis / systematic review · 2020
- Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis.Meta-analysis / systematic review · 2018
- Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.Observational study · 2016
Trials
- A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and GlycaemiaNCT00379769 · 15 posted results
- Effect of Pioglitazone on Insulin Resistance, Progression of Atherosclerosis and Clinical Course of Coronary Heart DiseaseNCT03011775 · 1 posted result
- Cardiovascular Outcomes in Patients With Type 2 Diabetes MellitusNCT03249506